You are wrong to a $100M company with QS-21 at least worth that. Any potential start of a phase III is big news for a microstock like this.
Historically GSK acquired Corixas for $300M plus $100M debt. Corixa's best asset at that time is the MPL vaccine adjuvant. QS-21 is equally important as MPL as it is used in 2/3 of future GSK's vaccine projects. Don't be surprised that GSK acquire this little biotech for around $300M.